

cell harvesting and promote engraftment of allogeneic donor and autologous gene-modified hematopoietic cells.

This interesting report appears to directly address the difficult problem of graft rejection that has challenged allogeneic hematopoietic cell transplantation for SCD. It also suggests that in gene therapy for SCD, in which there is transfer of both modified and unmodified hematopoietic cells, the gene-modified cell product must contain a sufficient fraction of corrected hematopoietic stem cells to re-model the marrow niche and ensure production of erythroid cells without oxidative stress. In addition, the short-term institution of RBC transfusions to reduce the fraction of sickle RBCs several months in advance of stem cell harvesting and transplantation might be prudent.

Conflict-of-interest disclosure: M.C.W. declares no competing financial interests. ■

REFERENCES

1. Park S-Y, Matte A, Jung Y, et al. Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversible by blood transfusion. *Blood*. 2020;135(23):2071-2084.
2. Nombela-Arrieta C, Silberstein LE. The science behind the hypoxic niche of hematopoietic

stem and progenitors. *Hematology Am Soc Hematol Educ Program*. 2014;2014:542-547.

3. Eaton WA. Hemoglobin S polymerization and sickle cell disease: a retrospective on the occasion of the 70th anniversary of Pauling's Science paper. *Am J Hematol*. 2020;95(2):205-211.
4. Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. *Nat Rev Dis Primers*. 2018;4(1):18010.
5. Patel SR, Zimring JC. Transfusion-induced bone marrow transplant rejection due to minor histocompatibility antigens. *Transfus Med Rev*. 2013;27(4):241-248.
6. Stenger EO, Shenoy S, Krishnamurti L. How I treat sickle cell disease with hematopoietic cell transplantation. *Blood*. 2019;134(25):2249-2260.
7. Esrick EB, Manis JP, Daley H, et al. Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients. *Blood Adv*. 2018;2(19):2505-2512.
8. Lagresle-Peyrou C, Lefrère F, Magrin E, et al. Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion. *Haematologica*. 2018;103(5):778-786.
9. Lemery SJ, Hsieh MM, Smith A, et al. A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers. *Br J Haematol*. 2011;153(1):66-75.

DOI 10.1182/blood.2020005114

© 2020 by The American Society of Hematology

TRANSPLANTATION

Comment on Burroughs et al, page 2094

Children with WAS: prefer early transplant!

Tayfun Güngör | University Children's Hospital Zurich–Eleonore Foundation

In this issue of *Blood*, Burroughs et al show impressive results in 129 pediatric patients who have undergone allogeneic hematopoietic stem cell transplantation (HCT) in North America between 2005 and 2015.¹

Wiskott-Aldrich syndrome (WAS) is an X-linked disorder caused by hemizygous mutations in the WAS gene leading to reduced/absent expression of the WAS protein, a major regulator of the actin cytoskeleton in hematopoietic cells. Affected boys experience severe microthrombocytopenia, eczema, and progressively deteriorating immune functions leading to autoimmunity, infections, and cancer. WAS is a life-threatening disease that can only be cured by allogeneic HCT¹⁻⁴ or gene therapy.⁵


Infants and children aged <5 years benefited most from HCT, with a 5-year overall survival (OS) of 94%, whereas patients aged ≥5 years achieved poorer outcomes (66%). Myeloid donor chimerism (DC) >50% was associated with superior platelet production. Preexisting autoimmune disease, mainly autoimmune cytopenias, responded favorably to HCT. The preparative regimen consisted of mainly busulfan-based reduced intensity/toxicity conditioning or myeloablative conditioning regimens, including serotherapy. Excellent results were obtained with HLA-matched

sibling donors (MSDs), 9/10-10/10 HLA-matched unrelated donors (MUDs), and unrelated cord blood transplants (UCBTs).

I remember in 2008 when one of my patients, at the age of 3 months, was diagnosed with WAS. Because of rare HLA alleles with no available MUD, at 2 years of age, the patient received a 7/10 (5/6) HLA-mismatched UCBT. He was negative for cytomegalovirus (CMV)/Epstein-Barr virus, and no virus-specific T cells were needed in his graft. The conditioning was myeloablative with busulfan/fludarabine. Therapeutic drug monitoring of busulfan was performed and resulted in a 50% dose reduction. Serotherapy with rabbit antithymocyte globulin (thymoglobulin; 4 × 2.5 mg/kg) was given to reduce the risks of graft-versus-host disease (GVHD). The patient achieved engraftment, and the HCT was uneventful. At latest follow-up in 2019, he exhibited 100% DC, normalized humoral immunity, and thymic function. Growth and length (both 75th-90th percentile), platelets (227 × 10⁹/L), and results of lung function tests were all normal, and there was no chronic GVHD. This was a satisfactory clinical outcome.

Burroughs et al show on a much larger scale that UCBT (30% of their reported transplant cases) has become a good alternative to MSD/MUD transplants in WAS and achieved a 5-year OS of 90%. Very young children and infants who are less likely infected with viruses such as CMV and with less disease burden can benefit from timely UCBT. Previous reports of UCBT in 90 patients reported inferior results, reaching OS rates of 75% mainly due to infectious deaths.⁴ The other finding of Burroughs et al that patients aged ≥5 years had poorer outcomes is not new. It is noteworthy, however, that the group of patients aged ≥5 years consisted of only 12 patients (9%), whereas 117 patients (91%) were <5 years of age at HCT. Statisticians do not favor age thresholds in medicine, but clinicians love them because they are helpful to facilitate therapeutic decisions.

It is far more interesting to understand why very young patients with WAS do better after HCT. WAS is undisputedly a progressive disease of the immune system, and risk scores as well as disease burden clearly increase with age.^{2,3} But what are the reasons to wait with HCT until the patient becomes ≥5 years of age? A milder clinical course or



Diagnostic and therapeutic proposals for optimization of HCT in WAS. aGVHD, acute graft-versus-host-disease; BM, bone marrow; Bu, busulfan; CB, cord blood; cGVHD, chronic graft-versus-host-disease; D, donor; EBV, Epstein Barr virus; GF, graft failure; haplo, haploidentical; MAC, myeloablative conditioning; PBSC, peripheral blood stem cells; R, recipient; rATG, rabbit; RIC, reduced-intensity conditioning; RTC, reduced-toxicity conditioning; Treo, treosulfan; TDM, therapeutic drug monitoring; UCB, unrelated cord blood; WASp, Wiskott-Aldrich-Syndrome protein.

nonavailability of suitable donors? What were the reasons that patients ≥ 5 years of age died after HCT? Previous splenectomy did not play a prognostic role. In the report of Burroughs et al, transplant-related mortality occurred mainly during the first year due to GVHD, infections, hemorrhage, and multiorgan failure, but the data are currently insufficient to answer these questions. Their rationale to perform transplants in children early and independent of their WAS scores is nevertheless convincing.

Moratto et al³ reported 5-year OS/transplant-related mortality/graft failure rates after HCT for WAS of 82%/18%/5%, respectively. In the study by Burroughs et al, these rates improved to 91%/9%/5%, although autoimmunity, declining DC, graft failure, grade 3 to 4 acute GVHD, and chronic GVHD remained serious complications after HCT.

Mixed DC in whole blood, T cells, and B cells were not directly associated with an increased incidence of de novo autoimmunity, which was an unexpected finding. In a prior article by Ozsahin et al,² de novo autoimmunity developed in 20% (19 of 96 patients) post-HCT and was associated with mixed DC (6 had full DC, and 13 had mixed or split DC). They occurred more frequently in MUD ($n = 9$) but less in MSD ($n = 5$) and haploidentical ($n = 5$) transplants. In the cohort of Burroughs et al, MUD still had the highest numbers (23%) of de novo autoimmunity,

this time independent of the degree of DC, whereas autoimmunity after MSD transplants and UCBTs was scarce (0% and 9%, respectively). Notably, de novo autoimmunity is not a rare finding after HCT for primary immunodeficiencies occurring with MUD transplants.⁶

Myeloid DC >95% and >50% to 95% were associated with normal median platelet counts, whereas lower DC (5%-50%) yielded clearly lower (median, $40 \times 10^9/L$) platelet counts. These DC analyses are extremely useful for comparison because gene therapy trials are currently rarely achieving platelet numbers $> 100 \times 10^9/L$.^{5,7}

Despite the general application of serotherapy, the incidence of grade 3 to 4 acute GVHD and chronic GVHD (15% and 17%, respectively) could have been lower, and there is no improvement over the results reported by Moratto et al³ (11.3% and 14.8%). Therapeutic drug monitoring of serotherapy, by serial measurements of plasma concentrations of antithymocyte globulin or alemtuzumab,⁸ may be one way to further reduce GVHD.

What would have happened if my anecdotal patient was diagnosed today and had chronic CMV infection? Volunteer donors in the registries have increased to ~ 34 million, and the chance to find a suitable MUD has clearly improved. In the report of Burroughs et al, 63 patients received MUD grafts (9/10 and 10/10-

HLA identical) and achieved satisfactory results. In case of unavailable MUDs/MSDs, haploidentical HCT by a CMV-seropositive relative using in vitro $\alpha\beta$ T-cell receptor/CD19 depletion or in vivo postcyclophosphamide T-cell depletion is a reasonable alternative (see figure).^{9,10} However, larger studies are needed to prove their efficacy in competition with gene therapy.⁵

Conflict-of-interest disclosure: T.G. declares no competing financial interests. ■

REFERENCES

- Burroughs LM, Petrovic A, Brazauskas R, et al. Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. *Blood*. 2020;135(23):2094-2105.
- Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. *Blood*. 2008;111(1):439-445.
- Moratto D, Giliani S, Bonfim C, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. *Blood*. 2011;118(6):1675-1684.
- Shekhovtsova Z, Bonfim C, Ruggeri A, et al; Eurocord, Cord Blood Committee of Cellular Therapy and Immunobiology Working Party of the EBMT, Federal University of Parana, Duke University Medical Center and Inborn Errors Working Party of the EBMT. A risk factor analysis of outcomes after unrelated cord blood transplantation for children with

Wiskott-Aldrich syndrome. *Haematologica*. 2017;102(6):1112-1119.

- Ferrua F, Cicalese MP, Galimberti S, et al. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study. *Lancet Haematol*. 2019;6(5):e239-e253.
- Yanir AD, Hanson IC, Shearer WT, et al. High incidence of autoimmune disease after hematopoietic stem cell transplantation for chronic granulomatous disease. *Biol Blood Marrow Transplant*. 2018;24(8):1643-1650.
- Fischer A. Platelets are the Achilles' heel of Wiskott-Aldrich syndrome. *J Allergy Clin Immunol*. 2019;144(3):668-670.
- Willemsen L, Jol-van der Zijde CM, Admiraal R, et al. Impact of serotherapy on immune

reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab. *Biol Blood Marrow Transplant*. 2015;21(3):473-482.

- Balashov D, Laberko A, Shcherbina A, et al. A conditioning regimen with plerixafor is safe and improves the outcome of TCR $\alpha\beta^+$ and CD19 $^+$ cell-depleted stem cell transplantation in patients with Wiskott-Aldrich syndrome. *Biol Blood Marrow Transplant*. 2018;24(7):1432-1440.
- Yue Y, Shi X, Song Z, et al. Posttransplant cyclophosphamide for haploidentical stem cell transplantation in children with Wiskott-Aldrich syndrome. *Pediatr Blood Cancer*. 2018;65(8):e27092.

DOI 10.1182/blood.202006079

© 2020 by The American Society of Hematology

CLINICAL TRIALS AND OBSERVATIONS

Comment on Neelapu et al, page 2106

The benefit of CAR T cells in older patients

Michael R. Bishop | University of Chicago

In this issue of *Blood*, Neelapu and coinvestigators have shown that older patients with advanced B-cell non-Hodgkin lymphoma (NHL) did just as well as younger patients receiving chimeric antigen receptor (CAR) T cells on the ZUMA-1 trial.^{1,2} Common perceptions, although not necessarily well founded, among oncologists and hematologists treating older patients with advanced NHL, such as diffuse large B-cell lymphoma (DLBCL), are that these patients are not fit enough to receive, do not want to receive, and will not derive any significant benefit if they do receive more aggressive therapies, such as hematopoietic stem cell transplantation (HSCT) or CAR T-cell therapy. The definition of an "older patient" is generally defined as patients >65 years of age, even though it has been argued that the more clinically relevant delineation is closer to 75 years, at which time comorbidities, physical dependency, and symptoms associated with aging become more prevalent.³ Such perceptions are also based on some fact, as age >60 years has been demonstrated to be an independent negative prognostic factor in patients with NHL.⁴ However, this observation from the early 1990s may not hold as great of significance today, as both therapy and supportive care have significantly improved over time. Indeed, the outcomes for older DLBCL patients to initial therapy with modern immunochemotherapy regimens are quite good, with 5-year overall survival rates approaching ~70%.⁵

The more significant challenge that arises is how to treat older patients with relapsed and refractory (R/R) disease. The treatment of choice in this situation would be some form of HSCT, either autologous or allogeneic. Outcomes for older DLBCL following autologous HSCT are actually similar to their younger

counterparts.⁶ Unfortunately, only a small minority of older patients over the age of 65 years is actually eligible for transplant because of lack of disease chemosensitivity. Trials utilizing CAR T cells targeting CD19 have resulted in relatively high response rates that are sustained in a significant minority of patients with R/R

B-cell NHL.^{2,7} In univariate analyses from these trials, CAR T cells appear to be equally efficacious among older patients receiving this treatment.

Despite these encouraging results, there may be similar perceptions and concerns that the use of CAR T cells may result in increased toxicities and have lower or limited efficacy in older patients with R/R DLBCL. To address these concerns, Neelapu and his fellow investigators from the ZUMA-1 trial performed a post hoc subgroup analysis of efficacy and safety of the autologous anti-CD19 CAR T-cell product axicabtagene ciloleucel (axi-cel) in patients ≥ 65 years as compared with patients <65 years of age with R/R aggressive B-cell NHL, the majority of which were DLBCL. Their analyses demonstrated most importantly that outcomes were nearly identical between the 2 age groups with slight trends favoring the 65 years and older age cohort, which comprised approximately a quarter of the study population, in regard to complete responses, duration of response, progression-free survival, and 24-month overall survival rate, which was 54%. These results were observed in the context of the 2 groups being relatively matched in regard to disease stage, tumor burden, and number of prior therapies. Of biologic interest, the axi-cel products in the older age cohort were noted to have similar peak and 28-day area-under-the-curve expansion to the younger cohort. In regard to toxicity, the overall incidences of cytokine release syndrome (CRS) and neurologic toxicities were not reported. The incidence of grade ≥ 3 CRS was similar and relatively low (7% vs 12%) between the 2 groups. However, the incidence of any grade ≥ 3 neurologic toxicities was notably higher (44% vs 28%) in the older age cohort, particularly in regard to encephalopathy, to which the investigators attributed age as a risk factor. There was minimal discussion in regard to long-term side effects, other than hypogammaglobulinemia, but they are assumed to have been minimal as the majority of studies on CART cells report resolution of most symptoms by 6 weeks after infusion.

As the options and outcomes for most older patients with R/R DLBCL and other advanced B-cell NHL are very limited, these are highly encouraging results. The immediate criticism is that these are highly selected patients, as is the case for all aggressive therapies, which require relatively normal organ functions and a